Table 2.
Characteristics of patients with positive and negative nasal SAA.
| Parkinson’s disease | iRBD | |||||
|---|---|---|---|---|---|---|
| negative nasal SAA, N = 14 | positive nasal SAA, N = 13 | p value | negative nasal SAA, N = 6 | positive nasal SAA, N = 12 | p Value | |
| Sex | 0.678 | 0.515 | ||||
| Female | 3 (21.4%) | 4 (30.8%) | 0 (0.00%) | 3 (25.0%) | ||
| Male | 11 (78.6%) | 9 (69.2%) | 6 (100%) | 9 (75.0%) | ||
| Age, years (SD) | 62.2 (9.95) | 65.9 (7.22) | 0.283 | 65.5 (9.80) | 66.1 (5.62) | 0.892 |
| Disease duration, years (SD) | 12.6 (5.49) | 12.2 (5.98) | 0.827 | 10.3 (9.97) | 7.15 (5.32) | 0.490 |
| H&Y stage, mean (SD) | 2.50 (0.52) | 2.62 (0.87) | 0.683 | NA | ||
| DBS surgery, n (%) | 10 (71.4%) | 7 (53.8%) | 0.440 | NA | ||
| Skin SAA positive, n (% of biopsied) | 11/12 (91.7%) | 4/7 (57.1%) | 0.117 | 18/18 (100%) | ||
| Subtype, n (%) | 0.282 | NA | ||||
| Akinetic-rigid | 11 (78.6%) | 7 (53.8%) | ||||
| Mixed | 3 (21.4%) | 4 (30.8%) | ||||
| Tremor-dominant | 0 (0.00%) | 2 (15.4%) | ||||
| Sniffin Sticks: TDI for PD, screening for iRBD | 19.4 (7.86) | 18.9 (5.09) | 0.870 | 7.33 (4.13) | 5.58 (3.00) | 0.384 |
| Positive RBD screening, n (%) | 7 (50.0%) | 5 (38.5%) | 0.830 | NA | ||
| NMSQ sum (SD) | 8.29 (2.33) | 11.4 (5.80) | 0.136 | 5.83 (5.78) | 6.58 (2.91) | 0.774 |
| MDS-UPDRS part 1, sum (SD) | 5.29 (3.75) | 8.30 (4.99) | 0.126 | 4.20 (3.19) | 5.60 (3.69) | 0.467 |
| MDS-UPDRS part 2, sum (SD) | 14.1 (5.38) | 12.1 (5.63) | 0.400 | 1.00 (1.73) | 1.40 (1.51) | 0.673 |
| MDS-UPDRS part 3, sum (SD) | NAa | 5.17 (2.48) | 3.08 (2.19) | 0.115 | ||
| MDS-UPDRS part 4, sum (SD) | 3.93 (4.29) | 4.62 (5.28) | 0.715 | NA | ||
| MoCA, sum (SD) | 27.3 (1.94) | 27.5 (2.02) | 0.748 | 28.0 (2.00) | 27.7 (1.78) | 0.737 |
| RBDSQ sum (SD) | NA | 10.2 (2.40) | 10.2 (2.17) | 1 | ||
| Orthostatic hypotension, tested in the clinic | NA | 2 (33.3%) | 4 (33.3%) | 1 | ||
| Pathological DaTscan | NA | 1/2 (50.0%) | 6/8 (75.0%) | 1 | ||
aA standardized MDS-UPDRS3 assessment in an off-state was not feasible in the PD cohort.